Antiangiogenic therapy for high-grade glioma

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Khasraw, Mustafa ^a   Ameratunga, Malaka S ^b   Grant, Robin ^c   Wheeler, Helen ^d   Pavlakis, Nick ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BARWON HEALTH   (Australia)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; LOMUSTINE; PLACEBO; VASCULOTROPIN; CAMPTOTHECIN; DACARBAZINE; IRINOTECAN; MONOCLONAL ANTIBODY; SNAKE VENOM; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL OUTCOME; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; META ANALYSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMICALLY INDUCED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; GLIOBLASTOMA; HUMANS; HYPERTENSION; LOMUSTINE; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SNAKE VENOMS;

EID: 84923021432     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008218.pub3     Document Type: Review

References (42)

1. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomised trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology Epub August 12 2013:3212-8.
2. Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse M, Buter J, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. Journal of Clinical Oncology 2013;31:abstr 2001.
3. 6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. Journal of Clinical Oncology 2013;31:abstr LBA2000.
4. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine 2014;370(8):709-22. [DOI: 10.1056/NEJMoa1308345]
5. Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter: initial report of the CORE study. 18th Annual SNO Scientific Meeting: Conference Proceedings. 2013; Vol. 15, issue Suppl 3:80.
6. Gilbert MR, Dignam J, Armstrong TS, Wefel JS, Blumenthal D, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine 2014;370(8):699-708. [DOI: 10.1056/NEJMoa1308573]
7. Herrlinger U, Schaefer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al.Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial. Journal of Clinical Oncology 2013;31:abstr LBA2000.
8. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ Systematic Reviews in Health Care 2001;323:228-47.
9. Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, et al. Comparative impact of tumor and treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled In RTOG 0825. Journal of Clinical Oncology 2013;31:abstr 2003.
10. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology 2009 Sep 16:Epub ahead of print.
11. CBTRUS Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the Uninted States. http://www.cbtrus.org/ (accessed 2008 15 August).
12. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Current Neurology Neurosciences Reports 2013;13:347.
13. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34(2):187-220.
14. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. Journal of the National Cancer Institute 1993;85(9):704-10.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
16. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 1994;79(2):185-8.
17. Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, et al. Tumor angiogenesis-therapeutic implications. New England Journal of Medicine 1971;285(21):1182-6.
18. Folkman J. What Is the evidence that tumors are angiogenesis dependent. Journal of the National Cancer Institute 1990;82(1):4-6.
19. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 2009;27(28):4733-40.
20. Gasparini G, Longo R, Fanielli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. Journal of Clinical Oncology 2005;23(6):1295-311.
21. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005;23(5):1011-27.
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions [updated September 2008]. The Cochrane Collaboration 2008, issue Version 5.0.1.
24. Kerbel RS. Tumor angiogenesis. New England Journal of Medicine 2008;358:2039-49. [DOI: 10.1056/NEJMra0706596]
25. Khasraw M, Lassman A. Advances in the treatment of malignant gliomas. Current Oncology Reports 2010;12(1):26-33.
26. Kreisl TM, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009;27(5):740-5.
27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumours of the Central Nervous System. Lyon: IARC, 2007.
28. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant gliomas. Journal of Clinical Oncology 1990;8(7):1277-80.
29. Machin D, Stenning SP, Parmar MKP. Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology 1997;9:100-14.
30. Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741-53.
31. Mirimanoff R-O, Gorlia T, Mason W, Van den Bent MJ, Kortmann R-D, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of Clinical Oncology 2006;24(16):2563-9.
32. Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
33. Scaringi C, Enrici RM, Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. OncoTargets and Therapy 2013;6:1079-95.
34. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis. JAMA 2005;292(8):972-7.
35. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. Journal of Clinical Oncology 2007;25(26):4127-36.
36. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66.
37. Taphoorn MJB, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason W, et al.Health-related quality of life (HRQoL) analyses in the AVAglio study, a randomized, placebo-controlled phase III trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma. Neuro-oncology. 2013; Vol. 15, issue Supplement: 3:232.
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92(3):205-16.
39. Wefel J, Pugh S, Armstrong T, Gilbert M, Won M, Wendland M, et al. Longitudinal analysis of neurocognitive outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Neuro-oncology. 2013; Vol. 15, issue Supplement 3:97.
40. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology 2010;28(11):1963-72.
41. Yan H, Parsons DW, Jin G, McLendon R, Ahmed Rasheed B, Yuan W, et al.IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009;360:765-73.
42. Zebrowski BK, Yano S, Liu WB, Shaheen RM, Hicklin DJ, Putnam JB, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clinical Cancer Research 1999;5(11):3364-8.